ReviewMaedica2026
Transarterial Radioembolization in the Treatment of Hepatocellular Carcinoma and Combination Strategies.
Review in Maedica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This review provides a comprehensive overview of transarterial radioembolization (TARE) using Yttrium-90 (Y-90), a minimally invasive locoregional therapy for HCC patients who are ineligible for surgical resection. Material and methods: A narrative review of the literature was conducted using PubMed/MEDLINE and Scopus databases. Studies focusing on patient selection, technical aspects, dosimetry, safety, oncologic outcomes and combination strategies were included. Clinical guidelines, prospective and retrospective studies, and comparative analyses were synthesized. A total of 43 key publications were synthesized, including landmark randomized controlled trials (SARAH, SIRveNIB, DOSISPHERE-01), recent meta-analyses and current clinical practice guidelines from EASL, AASLD and ESMO. Results: Transarterial radioembolization demonstrates high objective response rates and favorable survival outcomes across Barcelona Clinic Liver Cancer (BCLC) stages, with a favorable safety profile compared to systemic therapies. Personalized dosimetry approaches significantly improve response rates as demonstrated in the DOSISPHERE-01 trial. Combination strategies with immune checkpoint inhibitors and tyrosine kinase inhibitors show promising synergistic potential, supported by ongoing phase II/III trials including IMMUWIN, ROWAN and EMERALD-Y90. Conclusions: Transarterial radioembolization is a safe and effective locoregional therapy for HCC, with expanding indications including radiation segmentectomy with curative intent, downstaging for transplantation and combination with systemic therapies. Future research should focus on optimal sequencing, personalized dosimetry thresholds and identification of patients who are most likely to benefit from combination approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.